SVA

Philippines eyes Sinovac trial as early as November

Credit: REUTERS/THOMAS PETER

Sinovac Biotech may start late-stage trials of its coronavirus vaccine in the Philippines as early as next month, its food and drugs agency chief said on Thursday, after it hurdled the initial stage of the country's screening process.

MANILA, Oct 15 (Reuters) - Sinovac Biotech SVA.O may start late-stage trials of its coronavirus vaccine in the Philippines as early as next month, its food and drugs agency chief said on Thursday, after it hurdled the initial stage of the country's screening process.

The Food and Drugs Administration (FDA) expects to receive the Chinese drug maker's formal application for phase three clinical trials within two weeks and regulators will make a decision after their evaluation, FDA head Rolando Enrique Domingo said.

Domingo told reporters a November trial start was "possible".

Philippine President Rodrigo Duterte repeated on Wednesday that he preferred that his country source its COVID-19 vaccines from either China or Russia.

He also said he wanted the entire population vaccinated and has previously said he would not reopen schools until a vaccine was available.

A Sinovac spokesman confirmed that materials had been provided to the Philippines in the hope of starting Phase 3 trials, but gave no timeframe.

Jaime Montoya, a member of an expert panel screening applications for clinical trials and medications, told Reuters a technical evaluation of Sinovac had been completed and results already submitted to an ethics board for review.

The Philippines is also evaluating COVID-19 vaccines of Russia's Gamaleya Research Institute and Johnson & Johnson's Janssen for late-stage trials and is talking to U.S. drugmaker Pfizer Inc PFE.N and Moderna Inc MRNA.O as potential suppliers.

The Southeast Asian nation has 346,536 confirmed COVID-19, the highest in the region, and 6,449 deaths.

(Reporting by Neil Jerome Morales and Karen Lema in Manila; Additional Reporting by Roxanne Liu in Beijing; Editing by Martin Petty)

((neiljerome.morales@thomsonreuters.com))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SVA PFE MRNA

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More